13F Holdings
中文EN

BCAB BioAtla, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1826892 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY63.6%
TTM EPS YoY177.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-277.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,031.1%
Debt / equity—
Current ratio0.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-105.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue————$300,000
R&D expense$43.57M$63.09M$103.73M$79.35M$58.27M
SG&A expense$17.73M$21.85M$25.96M$28.79M$38.42M
Operating income-$59.30M-$73.94M-$129.69M-$108.14M-$96.44M
Interest expense———$0$3,000
Income tax$0$0$0$0$0
Net income-$59.61M-$69.78M-$123.46M-$106.48M-$95.40M
EBITDA-$58.93M-$73.02M-$128.47M-$106.94M-$95.11M
EPS (basic)-1.01-1.44-2.58-2.74-2.76
EPS (diluted)-1.01-1.44-2.58-2.74-2.76
Weighted avg. shares (diluted)58.83M48.57M47.78M38.93M34.56M
Balance sheet
Cash & equivalents$7.12M$49.05M$111.47M$215.51M$244.98M
Receivables$0————
Current assets$8.01M$51.23M$116.41M$220.43M$247.29M
PP&E, net$120,000$678,000$1.60M$2.73M$3.68M
Total assets$13.83M$52.42M$119.66M$225.74M$254.42M
Current liabilities$21.92M$14.54M$28.34M$23.13M$19.81M
Total liabilities$50.02M$38.16M$48.99M$45.40M$43.60M
Shareholders' equity-$36.19M$14.27M$70.67M$180.34M$210.82M
Shares outstanding1.27M58.10M48.08M46.34M35.80M
Cash flow statement
Operating cash flow-$48.20M-$71.94M-$104.02M-$90.42M-$62.21M
Investing cash flow—$0-$98,000-$265,000-$924,000
Financing cash flow$6.28M$9.51M$77,000$61.21M$69.51M
Depreciation & amortization$373,000$925,000$1.22M$1.20M$1.33M
Stock-based compensation$5.43M$8.92M$13.54M$14.56M$25.12M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.